Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
electroCore (Nasdaq: ECOR) announced promising results from clinical trials presenting at the 2022 International Stroke Conference. The trials explored the use of non-invasive Vagus Nerve Stimulation (nVNS) for treating acute stroke. Key findings showed a 65.9% reduction in relative ischemic lesion growth for nVNS compared to sham treatment. The trials indicated that nVNS was administered safely and met both primary and secondary endpoints. The company anticipates further research to establish nVNS's efficacy in stroke treatment.
electroCore (Nasdaq: ECOR) has completed enrollment for the TRANSIT study, a 97-patient, randomized, sham-controlled trial investigating non-invasive vagal nerve stimulation (nVNS) to alleviate postoperative ileus after colorectal surgery. Conducted in the UK, this study aims to improve recovery times and reduce healthcare costs associated with ileus, which affects 10-20% of colorectal surgery patients. Results from this study are anticipated later this year and will be presented at a medical congress.
electroCore (Nasdaq: ECOR) announced the presentation of three abstracts related to non-invasive vagus nerve stimulation (nVNS) for acute stroke treatment at the American Heart Association’s 2022 International Stroke Conference on February 9-11, 2022. Key presentations include a moderated poster on the acute treatment of ischemic or hemorrhagic stroke and two poster presentations investigating nVNS's effects on brain injury and ischemic stroke in rats. electroCore focuses on improving patient outcomes through its nVNS therapy, already FDA cleared for treating various types of headaches.
electroCore anticipates a 55% revenue increase for full-year 2021, projecting approximately $5.5 million compared to $3.5 million in 2020. The company is enhancing consumer access to its gammaCore therapy through new e-commerce platforms in the U.S. and U.K., alongside initiatives like gConcierge and gCDirect programs targeting healthcare providers. Revenue from government channels, including the VA and DoD, is expected to grow over 60%. The company also plans to broaden its clinical programs and explore acquisitions to further growth.
electroCore has announced that its gammaCore™ nVNS device has received Breakthrough Designation from the FDA for treating PTSD, demonstrating a 31% reduction in symptoms compared to sham treatment. PTSD affects approximately 15 million adults annually in the U.S., with significant impacts on quality of life. The breakthrough designation was supported by research from Emory and Georgia Tech. This new treatment represents a potential shift from traditional therapies, being non-invasive and with fewer side effects.
electroCore (Nasdaq: ECOR) has launched an online e-commerce shop in the United States for its gammaCore Sapphire™, a non-invasive vagus nerve stimulator for treating migraines and cluster headaches. This initiative enables patients to obtain prescriptions through telehealth consultations and purchase the device online. The platform, powered by Vytal, LLC, focuses on enhancing patient accessibility and engagement, aligning with the growing trend of direct-to-consumer healthcare. Chief Strategy Officer Joshua Lev emphasized that this move expands access to millions suffering from these conditions.
electroCore, Inc. (Nasdaq: ECOR) announced a peer-reviewed publication regarding its nVNS therapy for migraines, specifically from the PREMIUM II trial. Conducted across 27 U.S. sites, the study initially aimed to enroll 400 patients but closed with 231 due to COVID-19. Results showed a statistically significant reduction in monthly headache days (4.6 vs -3.0 for sham, p=0.05) and enhanced quality of life metrics. The therapy demonstrated particular efficacy in patients with migraine with aura, with a 5.5-day decrease in headache days. The findings underscore the potential of gammaCore for various migraine treatments.
electroCore, a commercial-stage bioelectronic medicine company (NASDAQ: ECOR), announced its management team will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The presentation is scheduled for January 10, 2022, at 7:00 am ET. Investors can register for the conference HERE.
A webcast replay will be available post-conference on the investor section of the company's website.
electroCore, Inc. (NASDAQ: ECOR) has secured exclusive distribution agreements for its gammaCore Sapphire™ non-invasive vagus nerve stimulator in several territories. The agreements are with Melidonia Health Services for Cyprus, Cyrus Medical Technologies for the UAE and Oman, and Express Medical Solutions LLC for Saudi Arabia and Bahrain. The agreements with Melidonia, Cyrus, and Medexsol have initial terms of three to five years.
These partnerships are part of electroCore's global expansion strategy to enhance accessibility to its therapeutic product for headache patients. Regulatory clearances are pending before sales can commence.
electroCore, a bioelectronic medicine company, has launched an e-commerce shop in the UK for its gammaCore Sapphire™ device, designed to treat menstrual migraines. The online platform allows patients to complete a healthcare questionnaire, receive product delivery, and receive training via video calls. Karly Hoggard, Director of Global Commercial Development, emphasized the importance of accessibility for women suffering from migraines, noting that 60% of them experience menstrual-related symptoms. The gammaCore device is FDA cleared and CE-marked for various headache treatments.